Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19.

MLA

Taiwo, Babafemi O., et al. “Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19.” The Journal of Infectious Diseases, vol. 228, no. 2, July 2023, pp. 133–42. EBSCOhost, https://doi.org/10.1093/infdis/jiad013.

APA

Taiwo, B. O., Chew, K. W., Moser, C., Wohl, D. A., Daar, E. S., Li, J. Z., Greninger, A. L., Bausch, C., Luke, T., Hoover, K., Neytman, G., Giganti, M. J., Olefsky, M., Javan, A. C., Fletcher, C. V., Eron, J. J., Currier, J. S., Hughes, M. D., & Smith, D. M. (2023). Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19. The Journal of Infectious Diseases, 228(2), 133–142. https://doi.org/10.1093/infdis/jiad013

Chicago

Taiwo, Babafemi O, Kara W Chew, Carlee Moser, David Alain Wohl, Eric S Daar, Jonathan Z Li, Alexander L Greninger, et al. 2023. “Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19.” The Journal of Infectious Diseases 228 (2): 133–42. doi:10.1093/infdis/jiad013.